Kiniksa Pharmaceuticals International, plc (KNSA)
Develops drugs to treat heart inflammation and related autoimmune conditions
$79.30+0.25%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+148.0%
The outlook
KNSA trades at $79.30, near the top of its 52-week range and above both key moving averages, reflecting a sustained uptrend. Analyst consensus strongly favors the stock, though the average price target sits about 1% below the current level. The trailing P/E of 87 is notably elevated, reflecting the market's pricing in significant expectations.
What’s behind the score
Analyst consensusStrong Buy — 1.1 avg of 8 analysts
Price trendAbove its 50- & 200-day averages
52-week range95% of the way from its 52-week low to high
Price targetAvg target -1% vs current price
Analyst price target
~12-month · 8 analysts$78.75average target-0.7% vs now
Now $79.30
Low $60.00High $99.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$6.10B
52-wk high
$81.97
52-wk low
$29.24
50-day avg
$56.99
200-day avg
$47.17
Trailing P/E
87.1